Neuromodulation: Technology at the Neural Interface This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Calendar of Events
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Tags: Professional Development Source Type: research

Abstracts from the 22nd Annual Meeting of the North American Neuromodulation Society
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Tags: Corrigendum Source Type: research

Table of Contents
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Tags: Issue Information – Table of Contents Source Type: research

Editorial Board
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Tags: Issue Information – Editorial Board Source Type: research

Aims and Scope
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Tags: Issue Information – Aims and Scope Source Type: research

Response to: Optimizing DBS Stimulation Parameters in Obsessive –Compulsive Disorder
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Authors: Eric A. Storch, Wayne K. Goodman Tags: Letter to the Editor Source Type: research

Long ‐Term Deep Brain Stimulation in Treatment‐Resistant Obsessive‐Compulsive Disorder: Outcome and Quality of Life at Four to Eight Years Follow‐Up
ConclusionsChronic DBS of ALIC provides long ‐term benefit up to four to eight years in trOCD, although not all patients take profit. Targeting the BNST was not particularly relevant since no patient appeared to benefit from direct stimulation of the BNST. Quality of life improved in DBS responders, documented by improved QoL scores and, e ven more important, by regaining of autonomy and improving psychosocial functioning. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Authors: Lotta Winter, Assel Saryyeva, Kerstin Schwabe, Hans E. Heissler, Joachim Runge, Mesbah Alam, Ivo Heitland, Kai G. Kahl, Joachim K. Krauss Tags: Clinical Research Source Type: research

Postoperative Externalization of Deep Brain Stimulation Leads Does Not Increase Infection Risk
ConclusionsOur data suggest that externalization of leads does not increase the risk of infective complications in DBS surgery. Lead externalization is a safe procedure which can provide a substrate for unique neurophysiological studies to advance knowledge and therapy of disorders treated with DBS. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Authors: Abteen Mostofi, Fahd Baig, Fotios Bourlogiannis, Micaela Uberti, Francesca Morgante, Erlick A. C. Pereira Tags: Clinical Research Source Type: research

Long ‐Term Outcome and Neuroimaging of Deep Brain Stimulation in Holmes Tremor: A Case Series
ConclusionsThe benefits of DBS in HT might not be always long lasting. Although QoL slightly improved, this change seemed to be independent of the motor outcome following DBS. The estimation of DBS target and VTA proximity could be a useful tool for DBS clinicians in order to facilitate the DBS programming process and optimize DBS treatment. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Authors: Panagiotis Bargiotas, T. A. Khoa Nguyen, Tobias Bracht, Melina M ürset, Andreas Nowacki, Ines Debove, Julia Muellner, Joan P. Michelis, Claudio Pollo, W. M. Michael Schüpbach, M. Lenard Lachenmayer Tags: Clinical Research Source Type: research

Utility of Deep Brain Stimulation Telemedicine for Patients With Movement Disorders During the COVID ‐19 Outbreak in China
ConclusionsDBS telemedicine could have a unique role to play in maintaining the delivery of DBS treatment and medical care to outpatients with movement disorders during the COVID ‐19 pandemic. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Authors: Chencheng Zhang, Kaiwen Zhu, Zhengyu Lin, Peng Huang, Yixin Pan, Bomin Sun, Dianyou Li Tags: Clinical Research Source Type: research

Ventral Capsule/Ventral Striatum Stimulation in Obsessive ‐Compulsive Disorder: Toward a Unified Connectomic Target for Deep Brain Stimulation?
ConclusionOur findings show that in VC/VS stimulation, the neural network associated with clinical outcome shows overlap with that of previously described for other targets namely the anterior limb of the internal capsula, the nucleus accumbens, or the STN, which supports the evolvement from the concept of an optimal gray matter target to conceiving the target as part of a symptom modulating network. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Authors: Tim A.M. Bouwens Vlis, Linda Ackermans, Anne E.P. Mulders, Casper A. Vrij, Koen Schruers, Yasin Temel, Annelien Duits, Albert F.G. Leentjens Tags: Clinical Research Source Type: research

Asleep Deep Brain Stimulation in Patients With Isolated Dystonia: Stereotactic Accuracy, Efficacy, and Safety
ConclusionsAsleep DBS may be an accurate, effective, and safe method for treating patients with isolated dystonia regardless of the stimulation target. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Authors: Hongxia Li, Tao Wang, Chencheng Zhang, Daoqing Su, Yijie Lai, Bomin Sun, Dianyou Li, Yiwen Wu Tags: Clinical Research Source Type: research

Similar Long ‐Term Clinical Outcomes of Deep Brain Stimulation With Different Electrode Targets for Primary Meige Syndrome: One Institution's Experience of 17 Cases
ConclusionThe curative effects of STN ‐DBS and Gpi‐DBS on patients with primary MS are similar. Both the STN and Gpi could be effective targets of DBS for primary MS. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Authors: Han Tian, Nan ‐xiang Xiong, Nian Xiong, Xiao‐ming Liu, Jing Rao, Wei Xiang, Xiao‐bing Jiang, Hong‐yang Zhao, Peng Fu Tags: Clinical Research Source Type: research

Tremor and Quality of Life in Patients With Advanced Essential Tremor Before and After Replacing Their Standard Deep Brain Stimulation With a Directional System
ConclusionsIn this cohort of advanced essential tremor patients who no longer had ideal tremor reduction with a standard system, replacing their deep brain stimulation with a directional system significantly improved their tremor and quality of life. Up ‐front implantation of directional deep brain stimulation leads may provide better tremor control in those patients who progress at a later time point. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Authors: Marie T. Kr üger, Josue M. Avecillas‐Chasin, Mandeep S. Tamber, Manraj K. S. Heran, Mini K. Sandhu, Nancy E. Polyhronopoulos, Natasha Sarai, Christopher R. Honey Tags: Clinical Research Source Type: research

Stimulation ‐Induced Dyskinesia After Subthalamic Nucleus Deep Brain Stimulation in Patients With Meige Syndrome
ConclusionSTN ‐DBS is an effective intervention for MS, providing marked improvements in clinical symptoms; SID may, however occur in the subsequent programming control process. Comparing patients with/without dyskinesia, the active contacts were located closer to the inferior part of the STN in patients with d yskinesia, which may provide an explanation for the dyskinesia. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - February 18, 2021 Category: Biotechnology Authors: Ning Wang, Kailiang Wang, Qiao Wang, Shiying Fan, Zonghui Fu, Feng Zhang, Lin Wang, Fangang Meng Tags: Clinical Research Source Type: research